Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Receivables - Net (2020 - 2025)

BioNexus Gene Lab's Receivables - Net history spans 6 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Receivables - Net rose 6.79% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 6.79%, while the annual FY2024 figure was $1.4 million, 72.14% up from the prior year.
  • Receivables - Net for Q3 2025 was $1.5 million at BioNexus Gene Lab, down from $1.9 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $4.2 million in Q3 2021 and bottomed at $799674.0 in Q4 2023.
  • The 5-year median for Receivables - Net is $2.2 million (2023), against an average of $2.2 million.
  • The largest annual shift saw Receivables - Net tumbled 72.12% in 2023 before it skyrocketed 87.47% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $3.4 million in 2021, then dropped by 14.55% to $2.9 million in 2022, then crashed by 72.12% to $799674.0 in 2023, then soared by 72.14% to $1.4 million in 2024, then increased by 10.58% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Receivables - Net are $1.5 million (Q3 2025), $1.9 million (Q2 2025), and $1.4 million (Q1 2025).